Discussion “Comparsion of the Bieoquvalence of Generic Versus Branded Clozapine”

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Dr. Meyer: How does the evidence presented today speak to the issues of bioavailability, bioequivalence, and interchangeability for clozapine? Are we convinced that there is no problem whatsoever with the 100-mg tablet of the generic product?

Dr. Lam: I think the reverse is true.

Dr. Glazer: The signal that is emerging from the available studies gives us reason for concern.